Livzon Pharmaceutical Group Inc. (01513.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

17.1x

EV/EBITDA

4.7x

Market Cap

HKD 18.09B

MomentumView details →

1D Return

+0.79%

YTD Return

−28.54%

RSI (14)

25.2

ValuationView details →

P/E (Fwd)

17.1x

EV/EBITDA

4.7x

Market Cap

HKD 18.09B

RSI (14)

25.2

MomentumView details →

1D Return

+0.79%

YTD Return

−28.54%

ProfitabilityView details →

Gross Margin

62.85%

Net Margin

15.60%

EBITDA Margin

25.25%

ROE (TTM)

12.49%

ROA (TTM)

7.07%

Asset Turnover

0.45x

GrowthView details →

Revenue YoY

−9.38%

EPS YoY

−21.25%

FCF YoY

+73.66%

Revenue CAGR 3Y

−1.63%

EPS CAGR 3Y

+3.63%

EBITDA YoY

−12.82%

EarningsView details →

EPS (Actual)

HKD 0.46

EPS Surprise

−37.51%

Beats (12Q)

0/12

Next Q EPS Est

HKD 0.60

Avg Surprise (4Q)

−37.51%

Rev Surprise

−27.92%

Capital & dividendView details →

Debt/Equity

0.32x

Current Ratio

1.55x

Quick Ratio

1.34x

Div Yield

8.06%

Div Rate

HKD 1.64

Div Growth 1Y

+37.06%

Financials snapshotView financials →

Revenue (TTM)

10.70B

Net Income (TTM)

1.67B

Op. CF (TTM)

3.30B

Next earningsOct 27, 2026 →

Latest newsMore news →

Livzon Pharmaceutical Group announced that its controlling subsidiary Livzon Mab received a drug registration certificate from China's National Medical Products Administration for the subcutaneous injection of Lekankitamab (Libaitan), a Class 1 therapeutic biologic approved for treating adult patients with moderate-to-severe plaque psoriasis.8d ago

Livzon Pharmaceutical Group announced a connected transaction to acquire a 3.5% stake in Xinbeijiang Pharmaceutical from Zhonghuiyuan for RMB 107 million in cash, increasing its holding from 87.14% to 90.64%.12d ago

Similar companies

Grand Pharmaceutical Group Limited00512.HK 健康元600380.SH HUTCHMED (China) Limited00013.HK Viatris Inc.VTRS 皓元医药688131.SH 华润双鹤600062.SH Find similar companies →

Latest newsMore news →

Livzon Pharmaceutical Group announced that its controlling subsidiary Livzon Mab received a drug registration certificate from China's National Medical Products Administration for the subcutaneous injection of Lekankitamab (Libaitan), a Class 1 therapeutic biologic approved for treating adult patients with moderate-to-severe plaque psoriasis.8d ago Livzon Pharmaceutical Group announced a connected transaction to acquire a 3.5% stake in Xinbeijiang Pharmaceutical from Zhonghuiyuan for RMB 107 million in cash, increasing its holding from 87.14% to 90.64%.12d ago